Dr. Ling has a keen interest in using cutting-edge genetic tools to develop treatment strategies for human diseases. She earned her Ph.D. in pharmacology from the University of Houston in 2018 where she published three peer-reviewed papers as the first author and received a Future Faculty Fellowship in 2015. Dr. Ling is currently a postdoctoral researcher in the laboratory of Dr. Steven Gray at the University of Texas Southwestern Medical Center. As a postdoc, she has been leading preclinical studies to establish an AAV-based gene therapy strategy for SURF1-related Leigh syndrome, a rare and devastating mitochondrial disease that typically presents in infancy and has no current treatment options. As this work moves into clinical trials, Dr. Ling’s future research endeavors include.